IL325865A - Compositions for delivery of plasmodium antigens and related methods - Google Patents

Compositions for delivery of plasmodium antigens and related methods

Info

Publication number
IL325865A
IL325865A IL325865A IL32586526A IL325865A IL 325865 A IL325865 A IL 325865A IL 325865 A IL325865 A IL 325865A IL 32586526 A IL32586526 A IL 32586526A IL 325865 A IL325865 A IL 325865A
Authority
IL
Israel
Prior art keywords
amino acid
plasmodium
seq
acid sequence
polypeptide
Prior art date
Application number
IL325865A
Other languages
English (en)
Hebrew (he)
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of IL325865A publication Critical patent/IL325865A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
IL325865A 2023-07-21 2024-07-19 Compositions for delivery of plasmodium antigens and related methods IL325865A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363515079P 2023-07-21 2023-07-21
PCT/US2024/038904 WO2025024335A2 (en) 2023-07-21 2024-07-19 Compositions for delivery of plasmodium antigens and related methods

Publications (1)

Publication Number Publication Date
IL325865A true IL325865A (en) 2026-03-01

Family

ID=92295739

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325865A IL325865A (en) 2023-07-21 2024-07-19 Compositions for delivery of plasmodium antigens and related methods

Country Status (6)

Country Link
EP (1) EP4746902A2 (de)
JP (1) JP2026524968A (de)
CN (1) CN121816193A (de)
AU (1) AU2024301077A1 (de)
IL (1) IL325865A (de)
WO (1) WO2025024335A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026162682A1 (en) * 2025-01-29 2026-08-06 BioNTech SE Compositions for delivery of plasmodium rh5 antigens and related methods

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5809076A (en) 1993-03-31 1998-09-15 Panasonic Technologies, Inc. Method for automatically independently providing asynchronous brouter address information to remote control units
US5965542A (en) 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
JP2002502831A (ja) 1998-02-03 2002-01-29 イネックス ファーマシューティカルズ コーポレイション 癌の治療に用いる血清に対して安定なプラスミド脂質粒子の全身供与
US6410328B1 (en) 1998-02-03 2002-06-25 Protiva Biotherapeutics Inc. Sensitizing cells to compounds using lipid-mediated gene and compound delivery
US6211140B1 (en) 1999-07-26 2001-04-03 The Procter & Gamble Company Cationic charge boosting systems
ATE291925T1 (de) 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
EP1519714B1 (de) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Verfahren und vorrichtung zur herstellung von liposomen
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
US6927663B2 (en) 2003-07-23 2005-08-09 Cardiac Pacemakers, Inc. Flyback transformer wire attach method to printed circuit board
CN1882693B (zh) 2003-09-15 2012-08-15 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
JP5639338B2 (ja) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド リポソームの製造システムおよび製造方法
EP3100718B1 (de) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Verbesserte zusammensetzungen und verfahren zur freisetzung von nukleinsäuren
EP2279254B1 (de) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Neue lipidformulierungen zur nukleinsäurezuführung
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
EP3699172A3 (de) 2008-11-10 2020-11-18 Arbutus Biopharma Corporation Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011066651A1 (en) 2009-12-01 2011-06-09 Protiva Biotherapeutics, Inc. Snalp formulations containing antioxidants
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
US20130017223A1 (en) 2009-12-18 2013-01-17 The University Of British Columbia Methods and compositions for delivery of nucleic acids
US8736243B2 (en) 2009-12-19 2014-05-27 Lanery Mgmt. Limited Liability Company Control multiplexor for a switch mode power supply
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
EP4481047A3 (de) 2010-06-03 2025-04-16 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von wirkstoffen
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
US9999673B2 (en) 2011-01-11 2018-06-19 Alnylam Pharmaceuticals, Inc. PEGylated lipids and their use for drug delivery
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換ｐｅｇ化脂質
US8762704B2 (en) 2011-09-29 2014-06-24 Apple Inc. Customized content for electronic devices
WO2013086322A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
DE21212055T1 (de) 2011-12-07 2022-08-04 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von wirkstoffen
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US9415109B2 (en) 2012-07-06 2016-08-16 Alnylam Pharmaceuticals, Inc. Stable non-aggregating nucleic acid lipid particle formulations
ES3032935T3 (en) 2013-10-22 2025-07-29 Translate Bio Inc Lipid formulations for delivery of messenger rna
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
WO2018081480A1 (en) 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
EP3374504B1 (de) 2015-11-09 2025-03-19 CureVac SE Optimierte nukleinsäuremoleküle
JP7261013B2 (ja) 2016-02-17 2023-04-19 カムリス インターナショナル インコーポレイテッド マラリアワクチンにおいて使用するための新規抗原
SI3445850T1 (sl) 2016-04-22 2021-12-31 BioNTech SE Postopki za zagotavljanje enoverižne RNA
GB201615298D0 (en) * 2016-09-08 2016-10-26 Oxford Univ Innovation Ltd And Yeda Res And Dev Company Treatment and prevention of Malaria
KR20190093816A (ko) 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
AU2019410737A1 (en) 2018-12-21 2021-06-10 CureVac SE RNA for malaria vaccines
CN118207228B (zh) * 2024-03-21 2025-03-14 中国科学院上海免疫与感染研究所 一种防治结合的多时期双靶点串联疟疾mRNA疫苗

Also Published As

Publication number Publication date
AU2024301077A1 (en) 2026-01-08
CN121816193A (zh) 2026-04-07
JP2026524968A (ja) 2026-07-24
WO2025024335A3 (en) 2025-03-06
WO2025024335A2 (en) 2025-01-30
EP4746902A2 (de) 2026-05-27

Similar Documents

Publication Publication Date Title
GB2605312B (en) Compositions and methods for delivery of RNA
IL316504A (en) RNA compositions for the delivery of monkeypox antigens and related methods
EP4117684A4 (de) Zusammensetzungen und verfahren zur verbesserten freisetzung antiviraler wirkstoffe
IL304123A (en) RNA transfer preparations and methods
EP4415690A4 (de) Zusammensetzungen und verfahren zur abgabe von mitteln
IL314324A (en) Pharmaceutical preparations for administration of herpes simplex virus antigens and related methods
AU2021413753A9 (en) Compositions and methods for delivery of rna
IL316049A (en) Musuntuzumab pharmaceutical preparations and methods of use
IL318706A (en) Compositions and methods for inducing proptosis
IL315862A (en) Angiotensinogen modulators and methods of using them
IL319410A (en) Compositions for administering Plasmodium CSP antigens and related methods
IL325898A (en) Compositions for delivery of plasmodium antigens and related methods
GB2593260B (en) Coupon wafer and method of preparation thereof
IL319414A (en) Compositions for delivering antigens at the liver level and related methods
IL321356A (en) Compositions and methods for targeted administration of TGFβ
CA3299278A1 (en) Compositions for delivery of plasmodium antigens and related methods
CA3299613A1 (en) Compositions for delivery of plasmodium antigens and related methods
HK40130252A (en) Compositions for delivery of plasmodium csp antigens and related methods
CA3267971A1 (en) Compositions for delivery of plasmodium csp antigens and related methods
IL319195A (en) Compositions and methods for RNA delivery
EP4312805A4 (de) Bildgeführte abgabe von zusammensetzungen und zugehörige verfahren
GB2595948B (en) Coupon wafer and method of preparation thereof
GB202211623D0 (en) Compositions and methods for delivery of truncated midkine proteins
IL327171A (en) Compositions and methods for reducing immunogenicity and improving the stability of antibodies
IL326066A (en) Compositions and methods for activation and maturation of immune cells